PharmExec Blog

UK Postpones Decision on Value-Based Assessment — Again

By Leela Barham.

Value-based Pricing (VBP) was first discussed as far back as 2007 by the UK’s consumer authority, the now defunct Office of Fair Trading (OFT).  The general concept of VBP was to set almost provisional prices based on the expected value of new medicines using immature data, with provisions to ‘correct’ the price should those expected benefits not be delivered in practice.  Read More »

Posted in Europe, Global, Guest Blog, Op-Ed, pricing | Tagged , , , , , , | Leave a comment

Email Marketing's Growing Maturity

Email marketing is still very much with us, despite much talk of its demise. But, writes Peter Houston, it has moved on from its “spammy” adolescence.

Scary tales of The-Next-Big-Social-Thing killing off the first digital marketing blockbuster have been building for years. McKinsey’s November 2013  iConsumer survey reported a 20 percent decline in email usage between 2008 and 2012, as the medium gave up ground to social networks and mobile messaging apps. But email, like so many well established communication channels, just won’t roll over and die.

Peter Houston

Peter Houston

Read More »

Posted in Marketing, Op-Ed, Patient Communication, social media, Strategy | Tagged , , | Leave a comment

EMA Calls Out to Companies Developing Ebola Treatments

The European Medicines Agency (EMA) is reviewing available information on Ebola treatments currently under development to “facilitate evidence-based decision-making” by health authorities.

At the moment there are no approved medicines to protect from or treat Ebola. Some experimental treatments have reportedly shown encouraging results in the laboratory or in animals, but they have not yet been fully studied in humans.

Over 5,300 cases of Ebola have been reported and more than 2,600 people have died. The current outbreak represents the widest geographical spread of the disease ever reported.

EMA has established a group of European experts with specialized knowledge in vaccines, infectious diseases and clinical trial design to contribute to the global response against Ebola. EMA Executive Director Guido Rasi has asked the Committee for Medicinal Products for Human Use (CHMP) to perform a formal review of the available scientific information; companies are invited to send all available quality, preclinical and clinical data about their treatments under development for review.  Read More »

Posted in Europe, Global, healthcare, Regulatory | Tagged , , | Leave a comment

EFPIA Promises Stronger Ties with China

The European Federation of Pharmaceutical Industries and Associations (EFPIA) reports that it has “strengthened its commitment in China”. Federation delegates are this week concluding a visit to Beijing to establish “a better understanding of the numerous healthcare reforms underway in China … and explore closer paths of cooperation in global drug development between China and Europe”.

The EFPIA delegation included global CEOs, EFPIA Director General Richard Bergstrom, and EFPIA President and Sanofi CEO, Chris Viehbacher. The delegates have taken part in a series of events in Beijing, including a conference on Translational Medicine and a workshop on Transparency and Good Governance.

Viehbacher commented: “EFPIA is committed to fostering productive relations with China… The research-based pharmaceutical industry is a global industry, and this visit marks an important milestone in fostering understanding between international health care leaders and promoting awareness about the advancements taking place in China’s life sciences sector.”

Posted in Europe, Events, Global, Regulatory | Tagged , , , | Leave a comment

CHC Stresses Privacy, First Amendment, Self-Regulation at DC meeting

This week members of the Coalition for Healthcare Communication (CHC) met to discuss issues in healthcare communications and marketing like privacy and security, off-label advertising and the Sunshine Act along with an update on the overall DC environment.

Nuala O’Connor, president and CEO of the Center for Democracy and Technology started the group off with a general talk about data collection and consumer privacy.

John Kamp, the Executive Director at Coalition for Healthcare Communication addressed the group regarding the group’s mission noting the importance of protecting 1st amendment rights in healthcare and pharmaceutical communications. Self-regulation is a hallmark of communicating in the field, Kamp noted. Kamp added that though it might be a controversial statement in other groups, members of the CHC see communication, marketing and education as being equally important to the healthcare industry as R&D. Read More »

Posted in Advertising, Marketing, Patient Communication, Sales | Leave a comment
  • Categories

  • Meta